First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
Fedro A. Peccatori, Giovanni Codacci-Pisanelli, Gunnar Mellgren, Barbara Buonomo, Eleonora Baldassarre, Ernst A. Lien, Ersilia Bifulco, Steinar Hustad, Emil Zachariassen, Harriet Johansson, Thomas Helland
Abstract
This study demonstrates for the first time in human that tamoxifen and its metabolites transfer into milk. Since tamoxifen has a complete oral bioavailability, a long half-life (>7 days) and may interfere with the normal development of the infant, mothers should not breastfeed during tamoxifen treatment.
Topics & Concepts
TamoxifenBreast milkBreastfeedingMedicineBreast cancerPharmacokineticsBioavailabilityBreast feedingHuman breast milkPregnancyInternal medicineOestrogen receptorEndocrine systemObstetricsEndocrinologyPhysiologyCancerHormonePharmacologyChemistryBiologyPediatricsGeneticsBiochemistryEstrogen and related hormone effectsCancer Risks and FactorsEffects and risks of endocrine disrupting chemicals